Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17949359 | 0.80 | TRPV4 (0.41) | TRPV4CA2CHKALOXL2LOX | |
| SCHEMBL30593162 | 0.77 | NT5E (0.41) | TRPV4CA2CHKALOXL2LOX | |
| SCHEMBL30340741 | 0.77 | TRPV4 (0.39) | TRPV4CA2CHKALOXL2LOX | |
| SCHEMBL29002089 | 0.77 | TRPV4 (0.39) | TRPV4CA2CHKALOXL2LOX | |
| SCHEMBL31119088 | 0.77 | TRPV4 (0.39) | TRPV4CA2CHKALOXL2LOX | |
| SCHEMBL17574583 | 0.77 | TRPV4 (0.39) | TRPV4CA2CHKALOXL2LOX | |
| SCHEMBL19899650 | 0.75 | CA2 (0.45) | TRPV4CA2CHKALOXL2LOX | |
| SCHEMBL2998384 | 0.75 | HSP90AA1 (0.38) | TRPV4CA2CHKALOXL2LOX | |
| SCHEMBL22448607 | 0.75 | TRPV4 (0.38) | TRPV4CA2CHKALOXL2LOX | |
| SCHEMBL2225528 | 0.75 | CA2 (0.45) | TRPV4CA2CHKALOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| CN-101611018-A | Heterocyclic sulfonamide with Edg-I antagonistic activity | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| EP-2094670-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008056150-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | TRPV4 4643/4885CA2 3649/4885CHKA 1318/4885 |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | EDF1, ERLIN1, ECE1 | TRPV4 3498/4885CA2 584/4885CHKA 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.